Wiebel Jaime L, Esfandiari Nazanene H, Papaleontiou Maria, Worden Francis P, Haymart Megan R
1 Division of Metabolism, Endocrinology, and Diabetes, University of Michigan , Ann Arbor, Michigan.
2 Division of Hematology/Oncology, University of Michigan , Ann Arbor, Michigan.
Thyroid. 2015 Sep;25(9):1026-32. doi: 10.1089/thy.2015.0062. Epub 2015 Aug 3.
Using the Surveillance, Epidemiology, and End Results-Medicare database, a substantial increase was found in the use of positron emission tomography (PET) scans after 2004 in differentiated thyroid cancer (DTC) patients. The reason for the increased utilization of the PET scan was not clear based on available the data. Therefore, the indications for and outcomes of PET scans performed at an academic institution were evaluated.
A retrospective cohort study was performed of DTC patients who underwent surgery at the University of Michigan Health System from 2006 to 2011. After identifying patients who underwent a PET scan, indications, rate of positive PET scans, and impact on management were evaluated. For positive scans, the location of disease was characterized, and presence of disease on other imaging was determined.
Of the 585 patients in the cohort, 111 (19%) patients had 200 PET scans performed for evaluation of DTC. Indications for PET scan included: elevated thyroglobulin and negative radioiodine scan in 52 scans (26.0%), thyroglobulin antibodies in 13 scans (6.5%), rising thyroglobulin in 18 scans (9.0%), evaluation of abnormality on other imaging in 22 scans (11.0%), evaluation of extent of disease in 33 scans (16.5%), follow-up of previous scan in 57 scans (28.5%), other indications in two scans (1.0%), and unclear indications in three scans (1.5%). The PET scan was positive in 124 studies (62.0%); positivity was identified in the thyroid bed on 25 scans, cervical or mediastinal lymph nodes on 105 scans, lung on 28 scans, bone on four scans, and other areas on 14 scans. Therapy following PET scan was surgery in 66 cases (33.0%), chemotherapy or radiation in 23 cases (11.5%), observation in 110 cases (55.0%), and palliative care in one case (0.5%). Disease was identifiable on other imaging in 66% of cases. PET scan results changed management in 59 cases (29.5%).
In this academic medical center, the PET scan was utilized in 19% of patients. Indications for the PET scan included conventional indications, such as elevated thyroglobulin with noniodine avid disease, and more controversial uses, such as evaluation of extent of disease or abnormalities on other imaging tests. PET scan results changed management in about 30% of cases.
利用监测、流行病学及最终结果-医疗保险数据库发现,2004年后分化型甲状腺癌(DTC)患者正电子发射断层扫描(PET)的使用大幅增加。根据现有数据,PET扫描使用增加的原因尚不清楚。因此,对一家学术机构进行的PET扫描的适应证和结果进行了评估。
对2006年至2011年在密歇根大学卫生系统接受手术的DTC患者进行了一项回顾性队列研究。在确定接受PET扫描的患者后,评估其适应证、PET扫描阳性率及对治疗的影响。对于阳性扫描,确定疾病的位置,并确定其他影像学检查中是否存在疾病。
在该队列的585例患者中,111例(19%)患者进行了200次PET扫描以评估DTC。PET扫描的适应证包括:52次扫描(26.0%)中甲状腺球蛋白升高且放射性碘扫描阴性,13次扫描(6.5%)中存在甲状腺球蛋白抗体,18次扫描(9.0%)中甲状腺球蛋白升高,22次扫描(11.0%)中评估其他影像学检查中的异常,33次扫描(16.5%)中评估疾病范围,57次扫描(28.5%)中对先前扫描进行随访,2次扫描(1.0%)中有其他适应证,3次扫描(1.5%)中适应证不明确。124项研究(62.0%)的PET扫描呈阳性;25次扫描在甲状腺床发现阳性,105次扫描在颈部或纵隔淋巴结发现阳性,28次扫描在肺部发现阳性,4次扫描在骨骼发现阳性,14次扫描在其他部位发现阳性。PET扫描后的治疗方法为手术66例(33.0%),化疗或放疗23例(11.5%),观察110例(55.0%),姑息治疗1例(0.5%)。66%的病例在其他影像学检查中可发现疾病。PET扫描结果改变了59例(29.5%)患者的治疗方案。
在这家学术医疗中心,19%的患者使用了PET扫描。PET扫描的适应证包括传统适应证,如甲状腺球蛋白升高且无碘摄取性疾病,以及更具争议性的用途,如评估疾病范围或其他影像学检查中的异常。PET扫描结果在约30%的病例中改变了治疗方案。